The value of combination therapy in adult acute myeloid leukemia with central nervous system involvement

Haematologica

Volumn 82, Issue 5, 1997, Pages 577-580

  Castagnola, Carlo ^a,b   Nozza, Andrea ^a   Corso, Alessandro ^a   Bernasconi, Carlo ^a  

^a UNIVERSITY OF PAVIA   (Italy)

^b FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

Author keywords

Acute myeloid leukemia; CNS involvement; Radio chemotherapy

Indexed keywords

ANTINEOPLASTIC AGENT; CYTARABINE; DAUNORUBICIN; ETOPOSIDE; IDARUBICIN; METHOTREXATE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LEUKEMIA; ADOLESCENT; ADULT; AGED; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CENTRAL NERVOUS SYSTEM TUMOR; FEMALE; HUMAN; INTRATHECAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; SKULL IRRADIATION; TREATMENT OUTCOME;

ADOLESCENT; ADULT; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COHORT STUDIES; CYTARABINE; FEMALE; HUMANS; LEUKEMIA, ERYTHROBLASTIC, ACUTE; LEUKEMIA, MONOCYTIC, ACUTE; LEUKEMIA, MYELOCYTIC, ACUTE; LEUKEMIA, MYELOID; LEUKEMIA, MYELOMONOCYTIC, ACUTE; LEUKEMIA, NONLYMPHOCYTIC, ACUTE; LEUKEMIA, PROMYELOCYTIC, ACUTE; MALE; MENINGEAL NEOPLASMS; METHOTREXATE; MIDDLE AGED;

EID: 0031451599     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Stewart DJ, Keating MJ, McCredie KB, et al. Natural history of central nervous system acute leukemia in adults. Cancer 1981; 47:184-96.
2. Kantarjian HM, Walters RS, Smith TL, et al. Identification of risk groups for development of central nervous system leukemia in adults with acute lymphocytic leukemia. Blood 1988; 72:1784-9.
3. Livraghi A, Pagnucco G, Santagostino A, et al. Risk of central nervous system (CNS) involvement in adult acute lymphoblastic leukemia (ALL). Analysis of 168 cases [abstract]. Haematologica 1996; 81:34.
4. Rees JKH, Gray RG, Swirsky D, Hayhoe FGJ. Principal results of the medical research council's 8th acute myeloid leukemia trial. Lancet 1986; 29:1236-41.
5. Holmes R, Keating MJ, Cork A, et al. A unique pattern of central nervous system leukemia in acute myelomonocytic leukemia associated with inv(16)(p13q22). Blood 1985; 65:1071-8.
6. Bassan R, Barbui T. Remission induction therapy for adults with acute myelogenous leukemia: towards the ICE age? Haematologica 1995; 80:82-90.
7. Steinherz P, Jereb B, Galicich J. Therapy of CNS leukemia with intraventricular chemotherapy and low-dose neuraxis radiotherapy. J Clin Oncol 1985; 3:1217-26.
8. Stewart DJ, Smith TL, Keating MJ. Remission from central nervous system involvement in adults with acute leukemia. Cancer 1985; 56: 632-41.
9. Simone JV. Treatment of meningeal leukemia. J Clin Oncol 1984; 2: 357-8.
10. Ghaddar HM, Plunkett W, Kantarjian HM. Long-term followig treatment of newly-diagnosed acute myelogenous leukemia with continous-infusion high-dose cytosine arabinoside. Leukemia 1994; 8: 1269-74.
11. Morra E, Lazzarino M, Brusamolino E, et al. The role of systemic High-dose cytarabine in the treatment of central nervous system leukemia. Cancer 1993; 72:439-45.
12. Morra E, Lazzarino M, Brusamolino E, et al. High dose Ara-c for the treatment of CNS disease in adult acute lymphoblastic leukemia. New Trends Ther Leuk Lymph 1986; 1:1-7.
13. Bennet JM, Catovsky D, Daniel MT, et al. Proposal for the classification of the acute leukemias: French-American-British (FAB) cooperative group. Br J Haematol 1976; 33:451.
14. Third International Workshop on chromosome in leukemia. Cancer Genet Cytogenet 1980; 4:95-142.
15. Morra E, Lazzarino M, Inverardi D, et al. Systemic high-dose ara-C for the treatment of meningeal leukemia in acute lymphoblastic leukemia and non-Hodgkin' s lymphoma. J Clin Oncol 1986; 4: 1207-11.
16. Plantier I, Lai L, Wattel E, et al. Inv(16) may be one of the only favorable factors in acute myeloid leukemia: a report on 19 cases with prolonged follow-up. Leuk Res 1994; 18:885-8.
17. Bleyer WA, Poplack DG. Prophylaxis and treatment of leukemia in the central nervous system and other sanctuaries. Semin Oncol 1985; 12:131-48.
18. George SL, Ochs JJ, Mauer AM, et al. The importance of an isolated central nervous system relapse in children with acute lymphoblastic leukemia. J Clin Oncol 1985; 3:776-81.
19. Anonymous. Towards an increasingly molecular-based, patient-oreinted treatment of acute myeloiud leukemia [editorial]. Haematologica 1996; 81:1.
20. Rudnick SA, Cadman EC, Capizzi RL et al. High-dose cytosine arabinoside (HDaraC) in refractory acute leukemia. Cancer 1979; 44: 1189-93.
21. Capizzi RL, Yang JL, Cheng E, et al. Alteration of the pharmacokinetics of high-dose ara-C by its metabolite, high ara-U in patients with acute leukemia. J Clin Oncol 1983; 1:763-71.
22. Van Proijen HC, Dekker AV, Punt K. The use of intermediate dose cytosine arabinoside (ID ara-C) in the treatment of acute non-lymphocytic leukemia in relapse. BrJ Haematol 1983; 57:291-9.
23. Van Proijen HC, Muus P, Reolofs JMP, et al. Does the metabolite uracilarabinoside inhibit cytosine arabinoside (ara-C) penetration into the cerebrospinal fluid during high-dose ara-C therapy? Scand J Haematol 1986; 36:123-6.
24. Chabner BA. Cytosine arabinoside. In: Chabner BA, Collins JM, eds. Cancer chemotherapy: principles and practice. Philadelphia: JB Lippincott; 1990. p. 154-79.